Instructions for use Hilo-Kea eye drops, multi-dose container 10 ml
Composition
active ingredients: hyaluronic acid, dexpanthenol;
1 ml of solution contains 1 mg of sodium hyaluronate and 20 mg of dexpanthenol;
Excipients: anhydrous citric acid, sodium citrate, water for injection.
Dosage form
Eye drops.
Main physicochemical properties: transparent colorless solution.
Pharmacotherapeutic group
Means used in ophthalmology. Artificial tear fluid substitutes and other neutral preparations.
ATX code S01X A20.
Pharmacological properties
Pharmacodynamics
The main goal of dry eye treatment is to increase the stability and volume of the precorneal tear film. It has been shown that hyaluronic acid, which is part of the drug in the form of sodium hyaluronate, has a chemical structure, molecular weight and rheological properties similar to mucin, a component of human tears. When applied topically, hyaluronic acid increases the stability of the precorneal tear film, has a positive effect on the epithelial layer, helps to increase the volume of tear fluid and corneal moisture, and also reduces tear evaporation from the surface of the eye.
Dexpanthenol is a biological precursor and alcohol analogue of pantothenic acid, a vitamin of group B. In ophthalmic use, dexpanthenol accelerates epithelialization, for example, after burns of the second and third degree, and promotes tissue granulation. It improves the symptoms of various forms of conjunctivitis and promotes the healing of mechanical damage to the cornea and reduces irritation caused by wearing contact lenses.
Pharmacokinetics
Sodium hyaluronate is not absorbed after topical application. There is no evidence that hyaluronic acid can penetrate the cornea. Even after direct injection into the inner chamber of the eye, only insignificant concentrations of hyaluronic acid were found in the bloodstream, which were rapidly metabolized by the liver. Therefore, systemic toxicity is not expected when using the drug.
When applied topically, dexpanthenol penetrates the skin, which allows high local concentrations to be achieved. In vivo, dexpanthenol is rapidly converted to pantothenic acid, which is widely distributed in the body, mainly as coenzyme A.
Indication
- For moisturizing the cornea and symptomatic treatment of dry eyes (dry eye syndrome);
- to stimulate re-epithelialization in superficial corneal lesions.
Contraindication
Hypersensitivity to any of the components of the drug.
Interaction with other medicinal products and other types of interactions
The simultaneous use of HILO-KEA® eye drops with other ophthalmic drugs should be avoided. If such a need still exists, these drugs should be instilled no later than 30 minutes before the use of HILO-KEA® eye drops. However, eye ointments should always be applied last.
Since, with topical ophthalmic application, the drug immediately reaches the target organ and exerts primarily a physical effect (moisturizing the surface of the eye) without systemic action, any drug interactions of the drug, other than physical interactions with eye drops for topical use, are not expected.
Application features
The drug HILO-KEA® is intended for individual use by one person only. The drug can be used while wearing contact lenses, which makes it more comfortable. However, to prevent possible incompatibility reactions with contact lens care products, it is recommended to wait approximately 30 minutes after inserting contact lenses before instilling the drug HILO-KEA®. In case of severe or persistent dry eye, you should consult a doctor.
When instilling eye drops, avoid any contact of the tip of the container with the eye or skin.
Use during pregnancy or breastfeeding
No controlled studies of the use of the drug during pregnancy or breastfeeding have been conducted.
However, the drug CHILOKEA® can be used during pregnancy or breastfeeding, since it does not have a systemic pharmacological effect.
Ability to influence reaction speed when driving vehicles or other mechanisms
In rare cases, immediately after instillation, HYLO-KEA® eye drops may cause brief blurring of vision, even when used properly at normal doses. Since this may increase reaction time, it is recommended to start driving a car or operating complex machinery some time after instillation of the drops, provided that visual clarity is restored.
Method of administration and doses
Usually, 1 drop of the drug is instilled into each eye 3 times a day. If necessary, the frequency of instillation can be increased. A significant increase in the frequency of instillation of the drug HILO-KEA® (for example, more than 10 times a day) can be carried out at the discretion of an ophthalmologist and under his supervision.
Note: The KOMOD container system allows the release of 10 ml of solution, which is approximately 300 drops. For technical reasons, a small number of drops remain in the container at the end of use.
Children
There are no data on the use of the drug in the treatment of children.
Overdose
No cases of drug overdose have been reported.
Adverse reactions
Since the drug HILO-KEA® does not contain preservatives, it is well tolerated even with prolonged use. In extremely rare cases, local hypersensitivity reactions have been reported, including irritation, burning sensation, redness, tearing, pain and itching in the eye, as well as swelling of the eyelids, which disappeared immediately after discontinuation of the drug.
Expiration date
3 years.
The drug should not be used after the expiration date indicated on the package.
The drug can be used within 6 months after first opening the container.
Storage conditions
Store at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
10 ml of eye drop solution in a multi-dose plastic container equipped with an airtight pump and a closed cap. 1 container in a cardboard box.
Vacation category
Without a prescription.
Producer
URSAPHARM Arzneimittel GmbH/URSAPHARM Arzneimittel GmbH.
Location of the manufacturer and address of its place of business
Industriestrasse 35, 66129 Saarbrucken, Germany.
